2023 RUNX1 Early Career Investigator Grant
Research Admin Offices:
A RUNX1 Early Career Investigator Grant is $180,000 over 3 years (maximum $60,000 per year may be requested).
- Health Sciences
Internal Deadline:December 7, 2022
Sponsor Deadline:December 21, 2022
The RUNX1 Early Career Investigator grant is a three-year award designed to fund research investigating strategies that will lead to the development of therapies that will prevent the transition from pre-malignancy to overt hematologic malignancy in patients with RUNX1-FPD.
The RUNX1 Research Program and ALSF host an annual scientific meeting that brings together grant recipients and other scientists. Grant recipients are expected to present their progress as part of the annual review.
- Applicant institutions must be based in the United States or Canada. Applicants need not be United States citizens. Funds must be granted to non-profit institutions or organizations.
- Applicants must have an MD, PhD, or MD/PhD (DO, MBBS or equivalent) and be within five years of their first faculty appointment as an Assistant Professor or equivalent tenure-track position. Associate and Full Professors are ineligible. If at the Instructor level, the applicant must submit a letter of support from their mentor at the sponsoring institution.
- A minimum of 75% of the applicant’s time during the award period must be allocated as protected time for all research activities. This percentage of time includes both activities on this grant and the applicant’s other research responsibilities.
- Applicants may have research grants from other funding sources during the award period, but there must be clear documentation of mechanisms to avoid scientific and budgetary overlap.
- Applicants must have research experience working in, and a deep understanding of, normal or malignant hematopoiesis and/or immunology.
- One resubmission of a previously unfunded application is allowed. Use the Resubmission section of the application to respond to the prior RRP/ALSF critique of the proposal. The response will be scored in the review process in addition to the criteria used for new applications. Resubmissions compete with new applicants for funding.
- A full proposal must be submitted that meets all guideline criteria as well as all eligibility criteria; otherwise, applications will be administratively rejected.
- Proposals will be reviewed by an independent panel of experts according to the NIH recognized peer-review process.
- Selection criteria include the following:
- Training/Education record.
- Publication record.
- Grant awards and research awards/recognition.
- Quality and overall ranking of research proposal based on the NIH 9-point scoring system.
- Alignment to overall goal of preventing hematologic malignancies in RUNX1-FPD and the feasibility of translating findings into the clinic.
If applying from the Faculty of Health Sciences, unless otherwise indicated, you no longer need to send documents to HRS Intake. Your first point of contact is your assigned Senior Grants Advisor.